Response to Immunotherapy in MMR-deficient Localized Colon Cancer

NCT05662527 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Camilla Qvortrup

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]